Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
St. John's Wort Dry Extract Ze 117 Drug Interaction Study in Healthy Volunteers
NCT03482817Phase 1Completed
- Sponsor
- Max Zeller Söhne
- Start
- Feb 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of St. John's wort extract Ze 117 in major depressive disorder (MDD), sponsored by Max Zeller Söhne. Primary endpoint: Ratio of Area Under the Curve from Time Zero to Last Quantifiable Concentration (Day 17 vs Day 1). Started Feb 2018; status: completed.
02
Drugs
St. John's wort extract Ze 117
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03482817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03482817.